# SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

> **NCT02048371** · PHASE2 · COMPLETED · sponsor: **Sarcoma Alliance for Research through Collaboration** · enrollment: 131 (actual)

## Conditions studied

- Liposarcoma
- Osteogenic Sarcoma
- Ewing/Ewing-like Sarcoma
- Rhabdomyosarcoma
- Mesenchymal Chondrosarcoma

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02048371
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2022-05
- **Final completion:** 2022-05
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02048371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02048371, "SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02048371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*